LONDON, Feb 9 (Reuters) – The chief executive of London-listed drugmaker AstraZeneca said on Thursday that discouraging tax policies in the UK led the company to shift plans for a $400 million investment in manufacturing from Britain to Ireland.
“We wanted to make (it) in this country but we made it in Ireland because the tax rate was discouraging,” Soriot told a media briefing after the company released its fourth-quarter 2022 results. He said the pharmaceuticals industry needed to see more supportive policies from the UK government.
Reporting by Natalie Grover and Maggie Fick
Editing by Tomasz Janowski
Our Standards: The Thomson Reuters Trust Principles.